AlloDirect, a direct sourcing platform connecting ambulatory surgery centers (ASCs) and health systems with AATB-certified tissue banks, announced that its platform is now available to hospitals and integrated delivery networks (IDNs), in addition to surgery centers. Facilities can source grafts directly from certified tissue banks, without a sales rep or a phone call to confirm what is on the shelf.
AlloDirect began rolling V2 out privately on April 22, 2026, to facilities and tissue banks that had been waiting on the multi-tenant build. Four new accounts, including the company’s first hospital partner, came onto the platform during the early-access phase. Today’s announcement opens V2 to the broader U.S. surgery center and health system market.
AlloDirect’s Founder and CEO said, “For decades our team watched surgery centers juggle multiple tissue vendors, wait days for reps to call back, and write off expired grafts they didn’t know they had. This is the platform we always wanted to build. Facilities source directly from certified tissue banks, with full visibility into what’s available and what it should cost.”
AlloDirect, a direct sourcing platform connecting ambulatory surgery centers (ASCs) and health systems with AATB-certified tissue banks, announced that its platform is now available to hospitals and integrated delivery networks (IDNs), in addition to surgery centers. Facilities can source grafts directly from certified tissue banks, without a...
AlloDirect, a direct sourcing platform connecting ambulatory surgery centers (ASCs) and health systems with AATB-certified tissue banks, announced that its platform is now available to hospitals and integrated delivery networks (IDNs), in addition to surgery centers. Facilities can source grafts directly from certified tissue banks, without a sales rep or a phone call to confirm what is on the shelf.
AlloDirect began rolling V2 out privately on April 22, 2026, to facilities and tissue banks that had been waiting on the multi-tenant build. Four new accounts, including the company’s first hospital partner, came onto the platform during the early-access phase. Today’s announcement opens V2 to the broader U.S. surgery center and health system market.
AlloDirect’s Founder and CEO said, “For decades our team watched surgery centers juggle multiple tissue vendors, wait days for reps to call back, and write off expired grafts they didn’t know they had. This is the platform we always wanted to build. Facilities source directly from certified tissue banks, with full visibility into what’s available and what it should cost.”
Copy to clipboard 
